Millstone Evans Group, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Millstone Evans Group, LLC
- $157 Billion
- Q3 2025
A detailed history of Millstone Evans Group, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Millstone Evans Group, LLC holds 90 shares of CPRX stock, worth $1,920. This represents 0.0% of its overall portfolio holdings.
Number of Shares
90
Previous 90
-0.0%
Holding current value
$1,920
Previous $1.95 Million
9.22%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CPRX
# of Institutions
385Shares Held
103MCall Options Held
0Put Options Held
277K-
Black Rock Inc. New York, NY18.7MShares$399 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$187 Million0.0% of portfolio
-
State Street Corp Boston, MA5.48MShares$117 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.25MShares$69.4 Million0.1% of portfolio
-
Morgan Stanley New York, NY3.18MShares$67.9 Million0.0% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.19B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...